• You can participate in the company presentation for free without registering for BIO KOREA 2009.
• Your participation and interests will be highly appreciated.

Sep. 17 (Thu) / Hall E2

Hanmi Platform Technology: LAPSCOVERY & ORASCOVERY	10:00~10:30
Hanmi has two kinds of platform technologies; LAPSCOVERY which can prolong a half-life of therapeutic proteins or peptides, ORASCOVERY which enables new development of orally available drug by potent PGP-inhibitor.

An Alzheimer Disease (AD) Inhibitor and Osteoporosis Inhibitor Developed by Integrated Drug Discovery Platform (IDDP™)

10:30~11:00

The IDDP™ (Integrated Drug Discovery Platform), a core technology of InnoPharmaScreen,Inc. , is a standard platform of drug discovery which can rapidly and economically find out lead materials and druggable candidates ranging from target analysis to lead optimization. The IDDP™ contains ‘structure-based in silico drug design, ‘Protein Chip-based high performance screening, in silico targeted screening, and ‘Cell based-Bioassay'. We are building up a sustainable pipeline of novel drug candidates which are applied to treat cancer, osteoporosis, Alzheimer disease, and Diabetes etc. Especially regarding to cancer, we have various candidates, such as a novel anti-osteoporosis agent (IPS-02001), anti-angiogenic peptide from hexapeptide library, EGFR kinase inhibitor, Erkinitib(IPS-01001, -01002, -01003) screened from chemical library using protein chip-base lead screening system. Recently, in order to diversify our pipeline, we have analyzed and developed various targets such as β-amyloid (Alzheimer disease), osteopontin (Osteoporosis) and DPPⅣ (diabetes). We are now developing the Integrated Drug Repositioning Platform (IDRP) to extend the applications range and patent life of a drug.

Cloning Without Restriction Sites by Using Red/ET Recombination

11:00~11:30

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size. Cloning using Red/ET has a number of advantages over conventional methods: First, it is independent of restriction sites as it does not rely on restriction enzymes for cloning. Second, there are no size limits of the DNA being modified, meaning it is a very useful tool in working with large vectors such as BACs or the E.coli chromosome. Also, there is no risk of unwanted mutations as all steps are controlled and take place in vivo. The final advantage is its speed, as many unnecessary and time-consuming conventional cloning steps can be avoided. The presentation will describe the use of Red/ET for the generation of targeting vectors and for the modification of the E.coli chromosome.

LifeQual Pharmaceuticals, Inc.	11:30~12:00

Introduction of PhytoHealth Corporation

13:30~14:00

With decreasing number of innovative new drug submissions and approvals, botanically-derived drugs emerge a niche markert for new drug development companies. Meanwhile, the long history of empirical use of Traditional Chinese Medicine (TCM) provides great advantage for the development of botanical new drugs. Phytohealth Corporation is the 1st publicly listed bio-pharma in Taiwan focusing on botanical new drug development. Thie benchmark of new drug development companies in Taiwan and its achievements will be presented in this session.

Development of Hemostatic Agent Recombinant Thrombin-like Enzyme	14:00~14:30
BioBud, Inc has expressed recombinant thrombin-like enzyme in yeast system. The recombinant protein is under pre-clinical stage.

Anti-obesity Drug ALS-L1023 Using Angiogenesis Inhibitor	14:30~15:00
Adipose tissue growth depends on angiogenesis. Anti-angiogenic botanical drug, ALS-L1023 is in phase II clinical trial as anti-obesity drug reducing adipose tissue.

LG Life Sciences: R&D Collaboration & Licensing-out Opportunities	15:00~15:30
LG Life Sciences has been developing new chemical drugs and biosimilars for 20+ years. Partnering opportunities will be presented following an introduction of our current R&D status and licensing opportunities.

Introduction of Daewoong R&D and Pipeline	15:30~16:00
- R&D center : Korea (Yong-In), China (Beiging), India (Hyderabad) - R&D pipeline : NCE (Neuropathic Pain : P1, Antiulcer , Antifungal etc), Biologics (Oncolytic Adenovirus : P1, Antibody), Botanical Medicines (Alzheimer, Arthritis), APIs (Contrast Media, Antibacterial), IMD, Generic etc.

Finding the Right Partner to Cost Effectively Enhance your Internal Pipeline

16:00~16:30

As drug discovery and development costs continue to rise, pharmaceutical companies are looking at options to cost effectively enhance their internal pipelines. Chemizon was established three years ago with the goal of becoming the ‘partner of choice’ for life science companies that seek external collaborations to develop breakthrough therapeutics. We have since grown rapidly, and currently have an integrated platform that our partners can leverage- a platform that includes medicinal chemistry, computational chemistry/structural biology, discovery biology, ADME/DMPK and pharmacology. This presentation will provide an overview on the current state of the life sciences industry and also describe Chemizon’s capabilities, therapeutic focus and business model in detail.

RegenPrime IR – Experts in Regenerative Medicine	16:30~17:00
RegenPrime’s natural scaffolds/matrices are killer application in regenerative medicine field. These cutting-edge technologies are based on ECM derived from porcine chondrocytes. These products have excellent properties; ① no or low immune response, ② biocompatibility, ③ biodegradability. ArtiFilm, the Company’s first product, is on clinical trial stage and sales at 2010 Q3.

Sep. 17 (Thu) / Hall E3

Korea Bio-IT foundry Kwangju Center - The Most Reliable Business Partner of POC R&D and Production	10:00~10:30
Korea BioIT foundry Kwangju center is established 2004, by government support. We provide foundry service for BIT convergence technology like POC products. We already get set automated SMT equipments, lateral flow chromatography(IVD) productive facilities, and biochemical laboratory. So you can find the most reliable business partnership from us.

Welcome to Green Jeollanamdo: Bioindustry of South Jeolla Province and Investment Opportunities

10:30~11:00

Green Jeollanam-do, one of the place with the most abundant bio-resources in Korea, welcomes your interest and investments. If you are looking for the place for business and research, then Jeollanam-do is the best. It produces most of crops, marine plants and eco-friendly bioproducts and has one-third of bioindustry-related local research institutes of Korea. Jeollanamdo Bioindustry Foundation (JBF) provides various business support services and co-research programs.

Adding Value an Effective Global Regulatory Strategy for Medical Devices and Diagnostics

11:00~11:30

Global Harmonisation of regulation in medical devices and diagnostics is streamlining the regulatory process, allowing approvals in multiple global markets based on a common set of product data and manufacturing controls. There are an increasing number of Mutual Recognition Arrangements between different regulators allowing regulatory decisions to be recognized in multiple markets. a well defined strategy allows rapid approvals to be gained for multiple markets by means of a correctly coordinated submission program. This presentation will describe current status and global regulatory trends in medical devices and diagnostics-with a particular emphasis on developing regulations in ASEAN and the ASEAN medical devices directive, which is due for implementation by all ASEAN members by 2015.

Malaysia’s Biotechnology Value Proposition

11:30~12:00

The presentation will be on the Malaysian’s Biotechnology Value Proposition including the following Background on Malaysian Biotechnology Corporation (BiotechCorp) Brief Description on Malaysia and Biotech Environment in Malaysia Financial Incentives and Healthcare Focus Areas Availability of Human Capital / Expertise in Healthcare Sector, Infrastructure and Opportunities to Venture in Biotechnology in Malaysia

How to Adopt Proteomics and Biomarkers in Our Company R&D?

13:30~14:00

Proteomics can be efficiently applied to discover phenotype-based biomarkers for diagnostic development and monitoring therapeutic responses. By establishing various horizontal and vertical networks, we have reached a competitive position for high-information discovery and validation of protein biomarkers. In this Business Forum, we’d like to provide, by presenting a model case for cancer biomarker discovery, current state-of-art of proteomics core-technology at the Functional Proteomics Center.

Charles River	14:00~14:30

Contract Research Organization (CRO) Collaboration Model in Asia

14:30~15:30

DreamCIS and ASKLEP Inc. have taken the lead in establishing a collaboration to meet the global clinical research needs. DreamCIS Inc. is a leading Korean full-service CRO with 10 years history. DreamCIS provides full-scope of clinical trial services for a broad and detailed range of therapeutic area in accordance with the standard Operating procedures consistent with both Korean regulations and global standards including ICH-GCP guidelines. ASKLEP Inc. is a Japan full-service CRO with almost 20 years of experience in Japan and has over 350 FT professionals. ASKLEP has a dedicated Global Clinical Trial Division where we have a expertise in global clinical trial consultation, regulatory, and global project managers. The interest has been recently moved to Asia and Asklep and DreamCIS have made a strategic partnership to perform the Asian study for the future. We establish the CRO collaboration model in Asia together and there are some more partner companies for this collaboration model.

Introduction - Korea Institute of Toxicology (KIT)	15:30~16:00
Korea Institute of Toxicology (KIT) is a world-class prestigious non-clinical contract research organization. We perform non-human primates toxicology test as well as carcinogenicity, reproductive toxicology test in accordance with FDA, OECD guidelines . Second Campus in Jeongeup will be constructed at 2010.

"Introduction of Morimoto-Pharma Group With CRO and Research Business in U.S.A. "

16:00~16:30

The founder of Morimoto-Pharma Group, Shuji Morimoto has more than 25 years experience in pharmaceutical industry, especially for R&D, Manufacturing, & CRO. Working in Takeda pharmaceutical company, the president Morimoto invented numerous products with more than 80 patents, and contributed to the development of Takeda’s top new drugs such as Leupron-Depo and Lansoprazole OD tablet. In addition, based on the tremendous network with more than 20 partner companies and over 10,000 drugs related experts he has accumulated, he established Morimoto-Pharma Group, a total service provider related to Pharmaceuticals offering services in the fields of ①Clinical Trials, ②Consulting, ③International Trading, ④R&D, ⑤Licensing, not only in Japan, but also in China, Korea and U.S.A. We would like to introduce our key service areas which are diverse in each country, and present how we can support you and your company who wants to challenge in a new market and in a new area.

Challenges and Opportunities of siRNA Delivery Systems

16:30~17:00

These days, many multi-national pharmaceutical companies such as Roche, Merck, Alnylam Pharmaceuticals, and Opko Health has launched siRNA delivery systems for gene therapy of genetic diseases and cancers. Until now, the field of gene delivery is an initial developmental stage. Development of novel gene delivery system using nanosized polymeric or inorganic nanoparticles for efficient and target specific delivery is a fundamental technology. In our group, PEGylated siRNA system was developed, showing enhanced serum stability and superior gene silencing effect in vitro and in vivo, compared to naked siRNA. More recently, our research group invented multimeric siRNA conjugates having cleavable linkage (disulfide bond), which exhibited superior cellular uptake and gene silencing effect for various cancer cells and in an animal model. These systems might be potentially applied for clinical applications of siRNA therapeutics.

Sep. 17 (Thu) / Hall E4

Novel Biochemical Marker for Myocardial Infarction Diagnosis & Novel Therapeutic Vaccine for Obesity

10:00~10:30

(I) SJ-NCM: Presently, three biochemical markers, ie CKMB, troponin, and myoglobin are used simultaneously and complementarily to diagnose Myocardial Infarction. SJ-NCM is a early-releasing and highly specific novel biochemical marker and is applied to point-of-care test kit for diagnosis of myocardial infarction. (II) SJ-BRV: An effective and safe obesity vaccine that blocks the storage of lipids at tissues by utilizing an Apo B-100 mimetic peptide as antigen. Anti-obesity mechanism, its efficacy and safety of the SJ-BRV will be discussed.

Introduction and Progress of GCC’ Vaccine and Biologics Pipeline	10:30~11:00
GCC(Green Cross Corp.) is the largest vaccine company in Korea and obtained approval of vaccine for seasonal influenza from KFDA last July, Other vaccines for avian influenza and swine influenza will be commercially available soon.

ViruSure Forschungs und Entwicklungs Gmbh

11:00~11:30

ViruSure Gmbh is a service provider in the area of virus and prion safety testing for the biopharmaceutical product manufacturers. It serves the biopharmaceutical sector in the pathogen safty testing of human and animal biological medicinal products, including: Vaccines Monoclonal Antibodies Recombinant Proteins Human Plasma and Blood Derived Products Gene Therapy Products The ViruSure laboratories are certified according to Good Laboratory Practice (GLP) under the Austrian GLP certification program.

US FDA Biological New Drug, Apitox – Phase III Clinical Trial

11:30~12:00

Apitox was formulated in the US, and approved IND (#3142), completed up to Phase IIa, but couldn’t continue due to lack of funds. We started all over again in Korea from 1990, and approved as a new drug in 2003 (KFDA). The additional study of Phase II is on progress under the new IND (#13754), and expected to be completed by 12/2009(CDER/FDA). We expect the Phase III could begin in 3/2010, and get an approval as a new biological drug in 12/2011(CBER/FDA).

New Avenues for a Fruitful Biomedical Cooperation Between Korea and the Heart of Europe

13:30~14:00

The world’s first measles, rubella, hepatitis B, meningitis and cervical cancer vaccines were developed in Wallonia (south Brussels). The region also hosts the world leaders in epilepsy treatment and proton therapy for cancer. And drug manufacturers in Wallonia, working in tandem with university laboratories on R&D, have contributed to major advances in the fight against global pandemics like tuberculosis, malaria, AIDS, cancer and neurodegenerative diseases. For nearly fifty years, Wallonia has been fostering understanding and know-how in molecular biology, genomics, proteomics, stem cells, medical appliances and equipment – all leading-edge technologies in the life sciences field, up to and including cell research (ADN, ARN, proteins, human genomes, etc) and the development of innovative diagnostics and therapies. With 76 biotechnology companies, representing 74 percent of Belgian biotechnology, the industry has an annual turnover of € 2.7 billion, with 80 percent of its work focused on healthcare, and employs about 10,000 people. Companies present include Pfizer, Johnson & Johnson, CooperVision, Baxter, GSK Biologicals, UCB, IBA and Eurogentec. The last four are all home-grown organizations that have since gone global: when Jean Stephenne, the present CEO and General Manager of GSK Biologicals, the ‘vaccine’ offspring of GlaxoSmithKline, joined the company in 1974, it employed a mere 54 people. Today it has a payroll of 9,000 worldwide, 5,500 of them in Wallonia. The emergence and global presence of these world leaders reflects the standards of scientific excellence, academic and industrial, nurtured in the region. Wallonia offers all the links in the biotech value chain: R&D, production, clinical testing, registration and commercialization, as well as close relationships between companies and university and non-academic research centers. The region also provides targeted forms of assistance like the university Technology Transfer Offices, the incubator units operated by university spin-offs. The region features 300 private and public R&D centers employing over 11,000 researchers. One-quarter, or 19,000, of the undergraduates at the three university systems of Louvain-la-Neuve (UCL), Brussels (ULB) and Liege (ULg) are all studying biomedical sciences, and one-fifth of the 5,000 PhDs are working on theses in this field. The BioWin cluster BioWin, is dedicated to the healthcare sector and related biotechnologies. BioWin, headed by Jean Stephenne of GSK Biologicals and Michel Goldman of the Institute of Medical Immunology/ULB, aims to become a world leader in fighting cancer, disorders of the immune system and diseases of the brain. The plan is to accelerate innovation by linking up universities and the private sector, and helping the smaller players in the field to achieve critical mass as a group. This pragmatic initiative reflects global market needs. The human capital of Wallonia is highly qualified, loyal and productive. In order to maintain these standards and ensure future growth, BioWin operates a series of training programs, in association with the private sector, universities, high schools and the Forem regional employment agency. Wallonia also has a chain of university hospitals with a total capacity of 30,000 beds, experienced personnel and state-of-the-art equipment. In addition, the Walloon government has launched a regional project to develop a biotech airbridge between Liege airport, Memphis and Singapore, the last equipped with a TNT Express facility linking Indonesia and China. Motorway links in the region provide a maximum one hour’s drive between the three principal biotech hubs.

Generation of Therapeutic Antibody Leads by Using Enormous Human Hierarchical Fab Antibody Libraries (HuDVH & HuDVL)	14:00~14:30
Hierarchical human antibody libraries composed of more than 1017 combinatorial diversity had been constructed by using noble Ex-phage and dual vector systems, and human therapeutic Fab antibody leads specific for various cytokines or tumor antigens are being isolated successfully.

Genetic Vaccines for Human and Animal Health

14:30~15:00

Traditional or classical vaccines are either based on an attenuated but still active microorganism as a modified life vaccine, MLV, or an inactivated and therefore non-replicating agens as killed vaccine, KV. MLVs are able to induce a very strong immune response but lack in biosaftey: MLV can revert, can recombine, can induce the disease. KVs have a high biosaftey level but need strong adjuvances for activation the immune system. Traditional or classical vaccines are also limited for some serious infectious diseases – no available vaccines but an unmet need. Genetic engineered vaccines, marker vaccines and the corresponding marker diagnostic will circumvent all these obstacles.

Introduction of SEOUL-CRO, Specialized in Asian Clinical Study

15:00~15:30

Seoul CRO was established as of April 22, 2009 to conduct clinical trials in cooperation with Tokyo CRO. This move was motivated by changes of PMDA review practices in 2008 when PMDA started to accept a clinical study report generated from an Asian region such as Korea, China and other Asian countries. Seoul CRO’s major function originates from MediHelpLine’s clinical division and it is invested by Cha Bio & Dios Tech and Tokyo CRO Group, which is one of the highest ranking CROs in Japan. Seoul CRO will realize ‘ON TIME LAUNCHING’ as well as provide site assistance with utilizing supports from SMO department and Asian Study Networks.

BioAtla LLC	15:30~16:00

Therapeutic Benefits of Multi-lamellar Emulsion (MLE) as a Topical Vehicle

16:00~16:30

Multi-lamellar emulsion (MLE), NeoPharm’s proprietary ingredients and technology, shows nearly identical structural properties to human stratum corneum intercellular lipids. As a vehicle for topical drugs, the structural uniqueness of MLE offers added therapeutic benefits, such as reducing the adverse effects of APIs, improving skin barrier function and skin hydration, and enhancing topical drug delivery. Various lipophilic APIs, including glucocorticoids, retinoids or tacrolimus can be easily incorporated into MLE formulations. We offer custom MLE formulation service for specific ingredients of your interests. We also expect KGMP and cGMP certificates will be granted by the end of 2009, which allows Neopharm to satisfy any regulatory guidelines world-wide.

Moving to The Next Level of Manufacturing	16:30~17:00
An introduction to DSM Biologics Industry issues concerning manufacturing of proteins and antibodies from mammalian cell systems How does DSM meet these challenges XD® process technology a paradigm shift for cell culturing and biofermenation How resulting challenges in DSP are tackled by DSM Biologics

Sep. 18 (Fri) / Hall E3

Novel Bio-Therapeutics for Ischemia (VM202) & Thrombocytopenia (VM501)

10:30~11:00

1) VM202: Novel Cardiovascular Therapeutic (Ph2) VM202 is a novel angiogenic medicine to diseases of ischemia, including coronary artery disease, peripheral artery disease, and also diabetic peripheral neuropathy (oxygen to neuronal cells). This consists of the proprietary pCK vector encoding the engineered hepatocyte growth factor (HGF) which can induce the restoration of blood flow to the affected areas through effective blood vessel collateralization. 2) VM501 / PEG-VM501: Recombinant Protein for Thrombocytopenia (Ph2) VM501 is a modified form of interleukin 11 (IL-11) targeting thrombocytopenia. Recombinant IL-11 protein is the only FDA-approved drug for Chemotherapy-Induced Thrombocytopenia (CIT), marketed as Neumega by Wyeth. However, due to severe side effect, its use is limited. In contrast, VM501 is more effective in low doses so it shows significantly less toxicity compared with Neumega. Recent Phase 2 trial results revealed significant therapeutic effects without any severe adverse events.

GenomeCAA and GenomeCAD - Computer Aided Analysis and Design of Microbial Whole Genomes

11:00~11:30

1. GenomeCAA: Computer-Aided Whole Genome Analysis Our GenomeCAA is world's first and only available integrated software suite for functional analysis of microbial genome, transcriptome, proteome, and metabolome data. GenomeCAA is based on our unique, proprietary, high quality, curated database of microbial (1) signal transduction (2) transport/secretion system and the effects of small molecules (3) transcriptional gene regulations by transcription factors (4) translational gene regulations by sRNAs (5) translational gene regulations by riboswitches (6) protein-protein interactions, and (7) metabolic pathways. 2. GenomeCAD: Computer-Aided Whole Genome Design Our GenomeCAD is world's first and only available solution for whole genome design. It is a phenotype-oriented computer-aided design platform for synthetic genomic research. GenomeCAD consists of tools and databases to fulfil the required knowledge while designing a synthetic organism. First is the information on functional organization of the biological molecules and their interactions within a living cell. Second is a comprehensive infrastructure for executing genome-scale design process from conception to final output of blueprints. The design flow of GenomeCAD includes designs for (1) Competency (2) Composition (3) Replication (4) Positioning (5) Organization (6) Regulation (7) Network (8) Epigenetics (9) Verification (10) Manufacturing.

Pine Tree Essential Oil and Pine	11:30~12:00
Bio food and medical usage of pine tree essential oil of Korea red pine and Korea pine-nut tree

Advancement in Adult Stem Cell Therapy	13:30~14:00
MEDIPOST Co., Ltd. is a specialized company in developing stem cell therapeutics using adult stem cells. It continues its development efforts with hospitals and corporations in Korea and overseas. Recently, its research has begun to show a slow but steady result toward resolving medical knotty-subjects while fulfilling medical safety and bioethical issues.

"NXCL-4950" - A Novel, Quick Effective Peripheral Blood Vessel Vasodilator

14:00~14:30

Neuronex Co., Ltd. recently developed [NXCL-4950], a functional cosmetic product applied on the skin that improves peripheral blood-flow disorders and that artificially expands blood vessels. NXCL-4950 is an advanced functional bio product developed on the basis of the cell membrane permeation technology of Neuronex and the accurate operation mechanism. Once it is applied to the skin, you can know that peripheral blood vessels are expanded within 10 seconds and that the area where it is applied changes to red, and also you can feel that hot feeling increases warmly as blood circulation is introduced after 5 to 10 minutes has elapsed.

InCell IT: A Novel Innovative Technology for In Situ Monitoring of Drug-Target Protein Interaction within Live Cell

14:30~15:00

InCell IT (In Cell Interaction Trap) is a novel technology that can elucidate the drug-target interaction in live human cells. Because of the native environment the target proteins are exposed to, InCell IT can detect the drug-target interactions that cannot be detected by conventional methods and it can reveal more clinically significant drug action. The technology can be applied to drug discovery in target identification, selectivity profiling and assay development. The technology has been published in Journal of American Chemical Society. (J. Am. Chem. Soc., 2008, 130 (49), 16466-16467) With its advantage in more clinically significant detection window, InCell IT technology can be useful in identification of targets for compounds from phenotypic assay screening and drug candidates showing unpredicted off-target activities, selectivity profiling of a promiscuously interacting compounds and assay development for a novel target protein which is difficult to purify and isolate for in vitro assays.

Novel Targets for the Treatment of Diabetes.

15:00~15:30

Scottish Biomedical has strong expertise in intracellular signaling which is particularly relevant to the field of metabolic disease. Scottish Biomedical has applied its strengths in Cell Systems Biology linked to medicinal chemistry to successfully complete a number many pre-clinical drug discovery projects in diabetes. These have been directed against targets both conventional and less conventional. Here we will focus on a number of the more innovative targets including cyclic nucleotide signalling molecules, phosphatases, 11 b-hydroxysteroid dehydrogenase and steroyl-CoA saturase. HTS screening has been completed and lead molecules with activity in cell-based assays and animal models identified.

Sep. 18 (Fri) / Hall E4

Shaperon Inc.: The Pipelines for Sepsis and Cancer Immunotherapy

10:00~10:30

We have received grant from Ministry of Science and Education from 2004 for the development of sepsis. We are currently undergoing for preclinical safety studies and we expect we can start phase I clinical study next year. In addition, we have received grant from the Ministry of Health and Welfare for the development of anti-Cancer immunotherapy, including Dendritic cell therapy and cameloid antibody. We are going to start preclinical safety study from next year. We are looking for investment and/or partners for preclinical and clinical studies.

Introduction of Gimhae Biomedical Center	10:30~11:00
Introduction of Biomedical Center, which was founded for the prior occupation and technical advance of biomedical industry of future, major business and Biomedical Techono-town development project to attract superior companies.

Corelli Consulting: Transactions in Life Sciences: Do It Right The First Time

11:00~11:30

Success is the goal of all life sciences companies, measured by achievements in revenue and reputation. These goals are achieved through sales, licensing and contract services based on a product & services portfolio, generated through internal R&D and/or by transactions with other companies or institutes. Through transactions, life sciences companies build a robust business model by strengthening product pipelines, extending company presence in emerging markets, eg in generics, and by expanded business offering. The key drivers for transactions, such as licensing, collaboration or M&A, are to access innovative or complementary technology, products close to the market, or new global markets. Corelli Consulting helps get your strategy future-ready. We assist clients to achieve these goals by thorough technical due diligence and strategic analysis. This presentation will use case studies to demonstrate our value-add in Commercial opportunity identification; Technical assessment and due diligence, Technology in- and out-licensing, Strategy development and review, Market review, Partnering identification and analysis, and Competitor analysis.

CK Life Sciences	13:30~14:00

Alginate Microcapsule Encapsulated Extract of Horseradish and Preparation Method Thereof	14:00~14:30
The objective of this study was to encapsulate the essential oil of horseradish within alginate microspheres. The essential oil was extracted using a distillation process. The success of the encapsulation was evaluated by examining the inhibition of Escherichia coli O157:H7, a food pathogen, by the alginate microspheres.

Nanoparticulation Using Fat and Supercritical Fluid	14:30~15:00
Converting poorly soluble drug substances into nano particles is a very effective strategy to improve bioavailability. Bio-Synectics developed a new innovative nanoparticulation technology NUFSTM, utilizing solid lipid and supercritical fluid. NUFSTM is a platform technology with wide applicability to many poorly soluble substances in the pharmaceutical and neutraceutical industries.

Novel Biomarkers, Drug Candidates & Bioinformatic Tools (KRIBB)	15:00~15:30
1. Omics-based biomarkers for diagnostics and treatment of cancers 2. Yeast cell remodeling technology to improve the quality of recombinant therapeutic proteins 3. Bioinformatic tools for genomics and proteomics 4. Bioflocculant for microalgae 5. Antimicrobial agent from plant extract